Zopa Retreatment and Vector Shedding in Adults With RRP
Key facts
- Who runs it
- Precigen, Inc
- Where
- Atlanta, Bethesda, and Cincinnati, United StatesSee the 3 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 30 people, planned
- Started
- 11 Jul 2024
- Expected to end
- 2 Dec 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Zopapogene imadenovec (Zopa)
- Record updated
- 15 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 18 years and older
- Clinical diagnosis of recurrent respiratory papillomatosis with histological confirmation of papilloma
- Cohort 1: Treatment-naïve with respect to Zopa
- Cohort 2: Received a minimum of four administrations of Zopa at 5 × 10\^11 PU per injection and require clinically indicated debulking procedures
- Presence of laryngotracheal papillomas accessible for endoscopic cleanout
- ECOG performance status 0 or 1
- Sexually active participants of reproductive potential must agree to use contraception during treatment and for 120 days for males and 6 months for females after last dose
- Ability to understand and sign informed consent
Who cannot take part
- Systemic corticosteroids >10 mg prednisone equivalent or other immunosuppressive medications within 14 days prior to dosing
- Other systemic RRP treatments or investigational agents within 30 days
- Conditions or therapies that increase risk or interfere with participation per investigator judgment
- History of heparin-induced thrombocytopenia or vaccine-induced thrombotic thrombocytopenia
- Active uncontrolled HIV, hepatitis B, or hepatitis C infection
- Known allergy to any study drug component
- Pregnant or nursing women
This trial is currently available in United States.
- Winship Cancer Institute, Emory UniversityAtlanta, United StatesContact: Mosope Oyewole, CRCTaking people
- National Institute Of HealthBethesda, United StatesContact: Shannon Householder, RNTaking people
- University of CincinnatiCincinnati, United StatesContact: Rebecca ReinertTaking people
About the trial
What the trial wants to find out
This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.
The 2 groups in the trial
- Cohort 1 Vector SheddingTreatment being tested
Zopa administered subcutaneously at 5 × 10\^11 particle units on Day 1, Week 2, Week 6, and Week 12. Samples for vector shedding to be collected from urine, feces, skin, and nasal tissue.
Treatment: Zopapogene imadenovec (Zopa)
- Cohort 2 RetreatmentTreatment being tested
Patients with prior treatment with Zopa (5 × 10\^11 PU per injection) and require clinically indicated debulking procedure
Treatment: Zopapogene imadenovec (Zopa)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Open-Label Study of Zopapogene Imadenovec Retreatment and Vector Shedding Evaluation in Adult Patients With Recurrent Respiratory Papillomatosis
- Record updated
- 15 December 2025